Janus Henderson Group
PHAT icon

Janus Henderson Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Janus Henderson Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$239K Hold
21,500
– – ﹤0.01% 2287
2025
Q4 		$357K Buy
+21,500
New +$307K ﹤0.01% 2143
2022
Q3 		– Sell
-1,092,212
Closed -$9.22M – 2588
2022
Q2 		$9.22M Sell
1,092,212
-909,230
-45% -$9.35M 0.01% 711
2022
Q1 		$27.2M Buy
2,001,442
+160,085
+9% +$2.59M 0.01% 676
2021
Q4 		$36.2M Sell
1,841,357
-106,645
-5% -$2.51M 0.02% 644
2021
Q3 		$62.5M Sell
1,948,002
-3,632
-0.2% -$121K 0.03% 488
2021
Q2 		$66.1M Sell
1,951,634
-2,814
-0.1% -$101K 0.03% 495
2021
Q1 		$73.4M Buy
1,954,448
+16,012
+0.8% +$670K 0.03% 449
2020
Q4 		$64.4M Buy
1,938,436
+369,640
+24% +$15M 0.03% 479
2020
Q3 		$57.5M Sell
1,568,796
-9,883
-0.6% -$342K 0.03% 465
2020
Q2 		$52M Sell
1,578,679
-88,898
-5% -$3.42M 0.03% 479
2020
Q1 		$42.2M Buy
1,667,577
+200,115
+14% +$6.69M 0.03% 494
2019
Q4 		$43.6M Buy
+1,467,462
New +$36.9M 0.02% 632

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Janus Henderson Group's PHAT Position: Q1 2026 in Review

Janus Henderson Group held its Phathom Pharmaceuticals (PHAT) position steady in Q1 2026 at 21,500 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

Janus Henderson Group first reported a position in PHAT in Q4 2019 and has held it in 13 quarters since. The position peaked at $73.4M in Q1 2021. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Janus Henderson Group held 21,500 shares of Phathom Pharmaceuticals worth $239K as of Q1 2026.
  • Janus Henderson Group left its Phathom Pharmaceuticals share count unchanged in Q1 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2287 holding.
  • Janus Henderson Group first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
  • Janus Henderson Group's Phathom Pharmaceuticals position peaked at $73.4M in Q1 2021.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.